What is it about?
The renin-angiotensin system has been established as an attractive target for pharmacological intervention since the discovery of first angiotensin-converting enzyme inhibitors (ACE-Is). In fact, these drugs are primarily used in the management of cardiovascular system-related diseases and renal insufficiency. Currently there are thirteen family members approved for use in humans. Here we discuss the pharmaceutical and chemical properties of the commercially-used ACE-Is.
Featured Image
Why is it important?
It seems unquestionable that the discovery and implementation of ACE-Is into clinical practice constitutes one of the most important events that stimulated a considerable progress in the pharmacological management of the cardiovascular system-related diseases. In fact, their beneficial actions such as cardioprotection, vasoprotection, renoprotection or cerebroprotection represent a high added value to their primary hypotensive effect thanks to which they finally became the key to the neurohormonal treatment of cardiac insufficiency.
Perspectives
The diversity of possible clinical applications for the investigated molecules result from the pleiotropic nature of the ANG II-related actions. In fact, the inhibition of ACE by ACE-Is has been considered to be an attractive strategy in the management of non-cardiovascular human diseases and disturbances, including: cancer, obesity, Alzheimer’s disease, Barrett syndrome, erythrocytosis, migraine, Duchenne muscular dystrophy, Raynaud’s syndrome, autoimmune diseases and Marfan syndrome.
dr Miłosz J. Regulski
Poznań University of Medical Sciences
Read the Original
This page is a summary of: Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors, Current Pharmaceutical Design, March 2015, Bentham Science Publishers,
DOI: 10.2174/1381612820666141112160013.
You can read the full text:
Resources
Contributors
The following have contributed to this page
